GlassScriptPhysician profile
Lynn Dudley
NPI 1316058084
$3,008.78
in general payments reported to CMS, 2019-2025
38 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $476 · 2022: $814 · 2023: $594 · 2024: $637 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696 · Consulting Fee: $22.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.76 |
| Consulting Fee | $22.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.79 | 2021-2025 | |
| Csl Behring | $382.29 | 2021-2025 | Hizentra |
| Grifols USA, LLC | $231.45 | 2021-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.34 | 2022-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $164.80 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $155.32 | 2022-2025 | NP Thyroid 60 |
| Exact Sciences Corporation | $149.29 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $123.38 | 2021-2025 | |
| Novo Nordisk INC | $103.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Redhill Biopharma INC. | $92.20 | 2021-2022 | |
| Antares Pharma, INC. | $89.01 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Ibsa Pharma INC. | $85.85 | 2021-2024 | Tirosint, Tirosint, Licart |
| Phadia US INC. | $72.76 | 2022-2025 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $66.63 | 2021-2023 | Cuvitru |
| Biohaven Pharmaceutical Holding Company LTD. | $57.58 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Dudley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.